Hyperfine Inc

Análisis de la acción Hyperfine Inc (HYPR)

$0.685

-0.059 (-8.65%)Al cierre

Loading chart…
Máximo
0.755
Apertura
0.751
Precio medio ponderado por volumen
0.70
Volumen
826.77K
Capitalización
68.77M
Mínimo
0.670
Importe
581.58K
EV/EBITDA, TTM
-0.87

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

hyperfinemri.com

Análisis de IA of Hyperfine Inc (HYPR)

Mantener

Hyperfine Inc (HYPR) is currently priced at $0.7227, which is significantly below its 52-week high of $1.94, indicating potential upside. However, the RSI of 36.757 suggests the stock is currently oversold, and the company has a gross margin of 50.72%, indicating it can maintain profitability despite challenges. The main risk is the negative net income, which was -$9,298,000 in Q2 2026, showing ongoing financial struggles. Given these factors, while there is potential for recovery, the current financial instability suggests a hold rather than a buy at this time.

Métricas de valoración

El PER previsto actual de Hyperfine Inc (HYPR) es 0.00, frente a su media de 5 años de -2.17.

PER previsto

Muy sobrevalorado
Media 5A P/E
-2.17
P/E actual
0.00
Sobrevalorada
-1.13
Infravalorada
-3.20

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-0.86
EV/EBITDA actual
-0.87
Sobrevalorada
0.95
Infravalorada
-2.67

Precio/ventas previsto

Valor razonable
Media 5A P/S
7.65
P/S actual
2.96
Sobrevalorada
15.80
Infravalorada
-0.49

Ballenas con HYPR en cartera

A

Alphabet Inc.

+ Con en carteraHYPR

+0.00%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-22 (ET)

08:30:00

Hyperfine Receives CE Mark and UKCA Approval for Optive AI Software

2026-10-08 (ET)

12:30:00

Major Averages Decline as Oil Prices Surge

08:00:00

Hyperfine Expects Q3 2026 Net Cash Burn of Approximately $5.6M

08:00:00

Management Expects 2026 Revenue of $20M-$22M

2026-09-28 (ET)

08:30:00

Hyperfine Appoints Roots Pharmaceutical as Exclusive Distributor for Kuwait and UAE

Noticias

Preguntas frecuentes sobre HYPR, respondidas por Alphio AI

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Hyperfine Inc (HYPR) is currently priced at $0.7227, which is significantly below its 52-week high of $1.94, indicating potential upside. However, the RSI of 36.757 suggests the stock is currently oversold, and the company has a gross margin of 50.72%, indicating it can maintain profitability despite challenges. The main risk is the negative net income, which was -$9,298,000 in Q2 2026, showing ongoing financial struggles. Given these factors, while there is potential for recovery, the current financial instability suggests a hold rather than a buy at this time.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar